Objective: To investigate efficacy and safety of lamotrigine (LTG) versus carbamazepine (CBZ) or valproic acid (VPA) in newly diagnosed focal (FE) and idiopathic generalised (GE) epilepsies in adolescents and adults. Methods: Open-label randomised comparative multicentre 24-week monotherapy trial in newly diagnosed epilepsy patients of !12 years of age. Patients with FE were treated with LTG or CBZ, those with GE received LTG or VPA. The primary efficacy variable was the number of seizure-free patients during study weeks 17 and 24. Results: Two hundred and thirty-nine patients were included. One hundred and seventy-six patients suffered from FE and 63 from GE. In the FE group, 88 patients each were treated with CBZ or LTG. Ninety-four percent of the CBZ patients and 89% of the LTG patients became seizure-free according to an intent-to-treat analysis (not statistically different). The rate of patients discontinuing treatment due to adverse events or a lack of efficacy was 19% with CBZ compared to 9% with LTG (not statistically different).
Introduction
Only about 50% of patients with epilepsy achieve adequate control following monotherapy with the initial antiepileptic drug (AED). 1 In order to avoid insufficient efficacy or tolerability in newly-onset epilepsy patients, AEDs with high effectiveness (high retention rates) in various age groups and both focal and generalised epilepsy syndromes would represent a considerable progress in epilepsy therapy. Controlled trials showing such effectiveness should be used as evidence to determine whether an AED is recommended as a first-line treatment for epilepsy.
In this context, lamotrigine (LTG) is a promising candidate. Several studies comparing its effectiveness in predominantly focal epilepsy (FE) syndromes with standard first-line AEDs such as carbamazepine (CBZ), phenytoin (PHT) and valproate (VPA) [2] [3] [4] found that it may have advantages in special patient groups, such as elderly patients. 5 According to the Veterans Administration studies, among the classical AEDs CBZ may be judged as the first-line therapy in FE. 6, 7 If the effectiveness of LTG was similar or better, one could argue that in special patient populations in which potential drawbacks of CBZ such as enzyme induction or sedating effects have to be strictly avoided, LTG might be an alternative and preferred in order to increase the probability of a satisfying first AED treatment regimen.
In addition, it has been shown that LTG is effective in generalised epilepsy (GE) syndromes such as idiopathic generalised epilepsies with absence, myoclonic and generalised tonic-clonic seizures on awakening 2, 3, [8] [9] [10] without having specific drawbacks which VPA as the leading AED in these indications may have, i.e., weight gain or increased teratogenic potential. 4, 11 In general, controlled studies are lacking in adolescents both with FE and GE to demonstrate the usefulness of LTG in this age group.
This study was therefore initiated to assess the effectiveness of LTG in newly-onset FE and GE in comparison with CBZ and VPA, respectively, as the accepted standard AEDs and to perform a controlled study in adolescent and adult patients. The clinical conditions reflected the realities of everyday practice wherever possible.
Materials and methods
This was an open-label randomised comparative multicenter trial to assess the efficacy and tolerability of LTG compared to standard antiepileptic drugs (AEDs) in newly diagnosed epilepsy patients of !12 years of age. At the time of the study, LTG was only licensed for focal epilepsy syndromes. Patients were recruited after unequivocal diagnosis of at least one epileptic seizure and electroclinical or imaging features indicating the onset of an epilepsy syndrome requiring AED treatment. The study was conducted in accordance with ICH-GCP guidelines and the Declaration of Helsinki. Local authorities and ethical committees of the participating 24 German sites had accepted the study protocol. After extensive information of patients and their legal representatives in case of an age below 18 years, written informed consent was obtained prior to inclusion.
Patients with FE were randomised to an LTG or CBZ monotherapy, whereas those with GE received a monotherapy with LTG or VPA which reflects a comparison with the standard first-line AEDs in Germany at the time of the study. Randomisation did not consider distinct syndromes within the FE or GE group. Thus, it was theoretically possible to have a relative majority of certain epilepsy syndromes within each subgroup treated by one or the other of the study drugs.
In order to confirm the correct diagnosis and epilepsy syndrome classification and thus the correct choice of the CBZ/LTG or the VPA/LTG treatment arm, we included as a unique methodological instrument that after recruitment of every patient the key data (seizure classification, EEG data, age at onset of the disease and syndrome classification) were anonymously sent by FAX to one of the principal investigators (BJS for adult patients, MAU for adolescent patients). Only if these principal investigators agreed with the syndrome classification, were patients allowed to continue. Four patients were excluded due to this additional assessment. Eleven further patients were excluded from the data analysis since they did not attend the following study visits (n = 9), diagnosis of an epilepsy was not 598 B.J. Steinhoff et al.
In the GE group, 30 patients received VPA and 33 LTG. During study weeks 17 and 24, 61% of the LTG patients and 84% of the VPA patients had become seizure-free (not statistically significant). The drop-out rate due to lack of efficacy or adverse events was 12% with LTG and 3% with VPA (not statistically different unequivocal (n = 1) or the necessity of antiepileptic drug treatment was questioned after recruitment (n = 1). Thus, the data of 239 of 254 patients could be included in the final data analysis. Whole treatment duration was 24 AE 2 weeks. Efficacy, tolerability and safety were evaluated at regular visits and by the additional use of a standardised tolerability questionnaire. In the event of a drop-out, a final visit was performed, which was identical to visit 4 at 24 weeks.
After randomisation of each subject, treatment with LTG, CBZ or VPA was started according to the German leaflet for each drug. LTG was distributed in 25 mg, 50 mg, 100 mg or 200 mg Lamictal 1 tablets, CBZ in the slow release form Timonil retard 1 in 300 mg and 600 mg tablets (Desitin Arzneimittel GmbH, Hamburg, Germany), and VPA as 150 mg, 300 mg and 600 mg Orfiril 1 tablets (Desitin Arzneimittel GmbH). According to the German leaflet and thus mandatory for the use in this study in adults and adolescents of at least 12 years, LTG monotherapy was started with 25 mg once a day for weeks 1 and 2 and then escalated to 50 mg once a day in weeks 3 and 4. From week 5 on, 100 mg once a day or 50 mg b.i.d. were established. In monotherapy, a maintenance dose of 100-200 mg was recommended. The investigators were allowed to escalate the dose further for clinical reasons up to a maximum of 500 mg. Similarly, they were allowed to titrate the CBZ or VPA doses according to the German leaflet. Thus, the CBZ preparation started with a daily dose of 200-400 mg in adults and with 200-300 mg in patients between 11 and 15 years. The recommended maintenance dose was 600-1200 mg in adults and 600-1000 mg in persons between 11 and 15 years. For VPA, a dose of 5-10 mg/kg body weight was given initially and increased every 4-7th day by approximately 5 mg/kg. The recommended daily maintenance dose was 600-1200 mg for children between 6 and 14 years or persons with a body weight of 20-40 mg, 600-1500 mg for adolescents from 14 years on or for persons with a body weight between 40 and 60 kg, and 1200-2100 mg for adults and persons weighing at least 60 kg. If clinically necessary, investigators would have been allowed to escalate CBZ and VPA further, individual tolerance provided.
The primary efficacy parameter was the percentage of patients being seizure-free between treatment weeks 17 and 24 on an intent-to-treat calculation. Focal and generalised epilepsies were analysed separately. In addition, we analysed the overall retention rates exclusively based on lack of efficacy or adverse events, the frequency of adverse events and the tolerability according to the tolerability questionnaire we used.
For the analysis of the primary efficacy endpoint logistic regression models were used: in the subgroup of FE, the factors 'treatment group' and a co-variable with the categories 'Focal without generalisation' and 'Focal with generalisation' were included.
In the model for GE, three factors were used: treatment group, age (<18, !18 years) and three differing epilepsy syndromes (juvenile absence epilepsy, juvenile myoclonic epilepsy, epilepsy with generalised tonic-clonic seizures on awakening).
For time-to-event data like ''leaving the study'' methods of the survival analysis were applied. Adverse event rates were compared by the Fisher's exact test.
Results

Baseline demographic and clinical characteristics
Out of 254 patients, 239 reached visit 1 and had therefore received study treatment. These patients were the subject of the data analysis. One hundred and seventy-six patients suffered from FE and were randomised to CBZ (n = 88) or LTG (n = 88). Sixtythree patients suffered from GE and were randomised to LTG (n = 33) or VPA (n = 30). At visit 4, 174 patients (78%) were still on trial medication. In the FE group, median doses after 26 weeks were 900 mg CBZ and 200 mg LTG in adults and 11.3 mg/kg CBZ and 2.4 mg/kg LTG in adolescents. In the GE group, the median doses were 1050 mg VPA (10.4 mg/kg in adolescents) and 150 mg LTG (2.1 mg/kg in adolescents). As shown in Table 1 , the demographic baseline distribution was equal within the GE and FE treatment arms with a markedly lower age in the GE group. Overall the proportion of adolescent patients was small (14%) and higher in the GE group (n = 28; 44%). In the FE group, however, the rate of adolescent patients was almost negligible (n = 5; 3%).
In the FE group, median doses at the end of the study were 900 mg CBZ (mean 839.2 AE 326.8; range 450-1800 mg) and 200 mg LTG (mean 170.6 AE 58.2; range 75-300 mg). In the GE group, the median doses were 1050 mg VPA (mean 1159.4 AE 463.0; range 600-2100 mg) and 150 mg LTG (mean 155.9 AE 60.5; range 75-300 mg). Doses per body weight were as follows: in the FE group, the median CBZ dose was 11.3 mg/kg (mean 11.44 AE 4.04; range 5.1-19.7), the median LTG dose was 2. 
Efficacy
Seizure freedom FE group Between treatment weeks 17 and 24, 94.3% of the CBZ patients (83/88) and 88.6% of the LTG patients (78/88) were seizure-free during that last period of the study. Eleven CBZ (12.5%) and 16 LTG patients (18.2%) had experienced seizures during the titration phase but became seizure-free during the study and particularly between study weeks 17 and 24. If these titration phase patients are excluded, the number of patients who stayed seizure-free during the whole study period without seizures during the titration phase was 72 (81.8%) with CBZ and 62 (70.5%) with LTG. The difference between the CBZ and LTG groups was not statistically significant. Table 2 summarises the data.
GE group
In the GE group, 83.3% of VPA patients (25/30) became seizure-free compared to 60.6% of LTG patients (20 of 33) (not significantly different) during study weeks 17 and 24 (intent-to-treat basis).
Seven LTG and six VPA patients suffered from seizures during titration but became seizure-fee. The marked, though not significant, difference between VPA and LTG resulted from a superiority of VPA in a special subgroup of patients with myoclonic seizures, i.e., with juvenile myoclonic epilepsy (JME): 10 patients in the LTG group (30.3%) and four patients in the VPA group (13.3%) suffered from this syndrome. Thirty percent of the patients treated with LTG (n = 3) and 75% of the VPA patients (n = 3) became seizure-free. Due to the small groups and the imbalance of distribution, a statistical comparison of this special subgroup was not performed. Among GE patients without myoclonic seizures, 73.9% (17/23) with LTG and 84.6% with VPA (22/ 26) became seizure-free.
Retention rates
Effectiveness of a treatment is mainly influenced by efficacy and tolerability. It is measured by the retention rate over the study period. Fig. 1a and b shows the overall retention rates for CBZ and LTG in the FE group and LTG and VPA in the GE group.
Seventeen patients (19%) stopped CBZ treatment during the study compared to seven patients 600 B.J. Steinhoff et al. (8%) who did not continue LTG in the FE group. One additional LTG patient dropped out due to a lack of efficacy which did not occur in the CBZ group. Retention rates considering adverse events and lack of efficacy only were therefore 81% for CBZ and 91% for LTG (not significant). Two of the 33 LTG patients with GE discontinued the study due to lack of efficacy. No VPA patient withdrew for this reason. The patients who withdrew LTG were both non-responders with JME. Withdrawals due to adverse events occurred twice (rash) in the LTG and once (hepatitis) in the VPA group. Thus, retention rates considering adverse events and lack of efficacy only, were 88% for LTG and 97% for VPA. Detailed figures for all patients who withdrew prior to the last study visit are shown in Table 3 .
Adverse events
At least one adverse event occurred in 81 patients in the CBZ group (91.0%) and in 68 patients in the FE LTG group (77.3%). In the GE group, the matching figures were 24 (72.7%) with LTG and 25 (83.3%) with VPA.
Serious adverse events occurred in eight patients in the CBZ group (9%), in six patients in the LTG FE group (7%), in five patients in the LTG GE group (15%) and in one patient in the VPA group (3%). However, in order to judge the drug safety in an adequate manner, it is more important to point out the drug adverse reactions, i.e., the adverse events the investigators suggested to be at least possibly related with the study drug. Such adverse drug reactions occurred in 65 (74%) of the CBZ patients, in 38 (43%) of the LTG patients with FE, in 15 (45.5%) of the LTG patients with GE, and in 16 (53%) of the VPA patients. Table 4 shows the 10 most frequent adverse drug reactions in each group.
Only under VPA a weight increase (mean 3.9 kg) was observed after 24 weeks. However, this specific side effect that was not apparent with CBZ or LTG did not lead to discontinuation.
Adverse events leading to discontinuation of the study drug and being judged as at least possibly related with the AED treatment were rash or dermatitis (n = 8; 9%), fatigue (n = 4; 5%), gait abnormality or ataxia (n = 2; 2%), depression (n = 1; 1%) and hyponatremia (n = 1; 1%) under CBZ, rash (n = 7; 6%; Figure 1 (a) Overall retention rates for CBZ and LTG in the focal epilepsy group (n = 176) and (b) for VPA and LTG in the generalised epilepsy group (n = 63). Note that retention rates drop markedly approximately from day 150 on. This did not result from a late-onset lack of efficacy or adverse events but from the fact that according to the study protocol (see Table 2 ) numerous patients decided to have visit 4 up to 2 weeks earlier than scheduled and thereafter were not followed anymore. trtgrp, treatment group. both groups (n = 121)), fatigue, nausea and leucopenia (n = 1 each; 0.8%) under LTG and hepatitis (n = 1; 3%) under VPA. Table 5 summarises the adverse events leading to withdrawal of the study drugs.
Discussion
This study evaluated the efficiency of LTG versus CBZ and VPA in FE and GE in a prospective comparative study. LTG was an effective and well-tolerated treatment for adolescents and adults with either FE or GE. In comparison to standard AEDs such as CBZ or VPA, LTG was similarly effective. We attempted to reflect clinical practice as much as possible and to escalate the dosage according to the German leaflet and to clinical criteria so that seizures during titration did not necessarily lead to a discontinuation of the study drug. It is apparent that during the initiation of LTG treatment, seizure-related drop-outs may occur more often due to the slow dose escalation mandatory for LTG. We have to admit that most probably a drop-out criterion ''first seizure under treatment'' would have led to lower LTG retention rates. However, the study shows that, under very realistic treatment conditions, LTG is similarly effective as CBZ in FE and as VPA in GE as suggested by previous trials. [2] [3] [4] [8] [9] [10] However, these studies were mainly either syndrome-specific but not comparative 8, 9 or they classified seizures but not syndromes. [2] [3] [4] In this study, we tried to classify the underlying newly-onset epilepsy syndromes as precisely as possible by an additional control of the correct diagnosis by two of the authors. In the comparative trial between topiramate and CBZ or VPA, which is a recently published study with a similar design, 12 the decision if the study drug was compared to CBZ or VPA was purely in the hands of the local investigators so that a considerable syndrome overlap between FE and GE was highly probable. Syndrome-specific conclusions were therefore not possible. In clinical practice, it may be essential to get an impression how effective a new drug may be in comparison with the gold standard. Thus, we feel confident in recommending the study design described here to obtain essential practical information in this respect. However, in order to overcome the partially imbalanced distribution of certain syndromes such as JME in our study, one should consider additional randomization according to such syndromes and hence a clearly higher total number of patients still allowing statistically relevant conclusions.
Since many more controlled clinical trials are available that demonstrate the good efficiency of LTG in FE, it is not surprising that the results of our study underline these experiences.
2, 3 We could confirm that LTG is less sedative than CBZ. Although this led to slightly lower retention rates under CBZ, in our study on adolescents and adults this trend was less obvious than in other patient groups such as elderly patients who are more susceptible for sedating adverse events and in which statistically significant advantages of LTG could be demonstrated. 5 However, the results of our study suggest that LTG may be equally effective and a first-line AED in patients in which the potential adverse 602 B.J. Steinhoff et al. event profile of CBZ or the possible results of its strong enzyme-inducing properties are a major drawback. In addition, we can add further information that this is also true if slow-release CBZ is used which was not the case in most of the previous comparative trials. In the FE group, we were not able to recruit enough adolescents in order to gain clinically relevant information in this age group. Our data did however not suggest specific disadvantages of either drug. In GE, the good efficacy of LTG was recognised early after its introduction and primarily described in open case studies. 9, [13] [14] [15] [16] [17] [18] [19] [20] [21] Furthermore, it was suggested that LTG might have advantages even in patients with GE refractory to VPA or ethosuximide. 22 The efficacy of LTG was also demonstrated in placebo-controlled trials in relatively small patient groups. 8, 10 These studies almost exclusively included patients with absence epilepsies with and without generalised tonic-clonic seizures or patients with generalised tonic-clonic seizures as the only seizure type. Some of the latter epilepsy syndromes were most probably included in the comparative trials aiming primarily at FE and comparing LTG with CBZ.
2,3 A recent retrospective study in idiopathic generalised epilepsy patients suggested a superiority of VPA 23 but naturally presented the methodological problems every retrospective survey cannot prevent. The major drawback of this study was certainly that the number of patients treated with VPA as first-line AED was considerably higher than the number of patients starting with LTG so that a selection bias was highly probable.
In general, we have to admit that our data in GE do not represent a satisfactory patient number for a comprehensive statistical analysis. Nevertheless, the group comparison showed no evidence for an inferiority of LTG compared to VPA in patients with GE with absence and generalised tonic-clonic seizures. It may be important that these GE syndromes Lamotrigine versus carbamazepine in newly diagnosed and generalised epilepsies 603 usually have a better therapy prognosis as JME and that the rate of JME patients was considerably higher in the LTG group. In general, it became apparent that VPA is an excellent drug in generalised epilepsies, but also that LTG may be an effective and well-tolerated alternative, especially if VPA-specific drawbacks such as teratogenic effects 11 or weight gain 4 are major arguments for the right AED decision.
As mentioned earlier, the rate of patients with JME was considerably lower in the VPA arm in spite of the initial randomization since we did not randomise further according to distinct epilepsy syndromes among the GE group. Our data may indicate that within the small subgroup of patients with myoclonic seizures VPA could be more effective. They are certainly not appropriate to draw definite conclusions concerning this question. Open studies reported the beneficial effects of LTG in JME 20, 24, 25 and sometimes claimed superiority over VPA. 26 This is further supported by a recent open study that demonstrated that in almost half of 63 patients with JME, an unsatisfactory course with VPA could be successfully switched to LTG monotherapy. 27 On the other hand, reports on the occasional specific exacerbation of myoclonic seizures in JME under the influence of LTG do exist. 25, 28 Furthermore, in severe myoclonic epilepsy of infancy the increase of myoclonic seizures was reported repeatedly. 29, 30 Consequently, the responder rates of patients with generalised myoclonic seizures according to open studies vary widely from 29% to 93%. 31 More data of controlled trial addressing this open and clinically relevant question are strongly recommended. We want to emphasise that the use of VPA as comparator in the GE group does not mean that VPA is not an established option in focal epilepsy syndromes as well. The value of VPA for the monotherapy of focal epilepsy syndromes is unquestionable. 7 Our study design just used the established first-line AED for focal (CBZ) and generalised (VPA) epilepsy syndromes in Germany at the time of trial.
Our study emphasises that LTG as the first monotherapy is equally effective and well tolerated in adolescent and adult patients with FE and GE. Furthermore, LTG was less sedative than CBZ and not associated with the problem of weight gain, which was specifically apparent with VPA. These findings suggest that the profile of LTG indicates specific patient populations in whom one may suggest to prefer LTG if AED treatment has to be initiated. Observations of longer treatment durations than the 24 weeks duration in our trial are necessary to evaluate better the advantages and disadvantages of each AED under practical conditions. Finally, we believe that the main and somewhat very encouraging finding of this study is that we did not find any particular difference between the three tested AEDs concerning any of the outcome measures and that therefore CBZ, VPA and LTG are equivalent in their effectiveness. CBZ and VPA proved to be very favourable options. We conclude that LTG is an important additional treatment possibility as monotherapy both in focal and generalised treatments and may be considered as potential first-line AED if the individual patient's profile requires to avoid disadvantages resulting from specific properties such as potent enzyme induction or the possible induction of weight gain.
